g(E)-pHLIP promote virus Immunity to destroy Cervical Cancer Cell

BACKGROUND: Cervical cancer treatment faces challenges in identifying specific targets within heterogeneous tumors. Current antitumor immunotherapy for cervical cancer is constrained by the lack of corresponding therapeutic targets. METHODS: We developed glycoprotein E (gE)-pHLIP nanomicelles, an antigen-targeting peptide particle anchored on cell membranes. This system enables tumor-targeted antigen release, labels tumor tissues, and leverages pre-existing immune responses for tumor elimination by "disguising" cancer cells as viral invaders. RESULTS: In animal models, pre-immunization with g(E) combined with g(E)-pHLIP treatment demonstrated suppressed tumor growth. Reduced tumor recurrence was observed post-treatment. The system successfully activated the body's antiviral immune response against labeled tumor cells. CONCLUSIONS: This study developed a novel protein-peptide system that labels cervical cancer cells, "disguises" them as viral invaders to the body, and subsequently eliminates tumors through the body's antiviral immune response.